Table 3.
Univariate and multivariate logistic regression analyses of study cohort.
| Factor | Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|---|
| N | HR | 95% CI | p-Value | HR | 95% CI | p-Value | |
| Age (years) | |||||||
| ≥65 | 594 | ||||||
| <65 | 700 | 0.75 | 0.70–0.85 | <0.001 | 0.8 | 0.7–0.9 | <0.001 |
| Sex | |||||||
| Female | 576 | ||||||
| Male | 718 | 1.2 | 1.1–1.4 | <0.001 | 1.4 | 1.1–1.5 | 0.001 |
| Tumor stage | |||||||
| Resected | 537 | ||||||
| Locally advanced | 134 | 1.8 | 1.4–2.2 | <0.001 | 1.8 | 1.2–1.5 | <0.001 |
| Metastasized | 623 | 2.6 | 2.2–3.0 | <0.001 | 2.5 | 2.1–2.9 | <0.001 |
| Localization | |||||||
| Head | 675 | ||||||
| Body | 125 | 0.95 | 0.76–1.2 | 0.618 | 0.86 | 0.6–1.1 | 0.249 |
| Tail | 208 | 1.20 | 0.99–1.4 | 0.058 | 0.98 | 0.8–1.2 | 0.862 |
| Overlap | 63 | 1.49 | 1.12–2.0 | 0.007 | 1.01 | 0.7–1.4 | 0.970 |
| Not specified | 223 | 1.50 | 1.26–1.8 | 0.001 | 1.11 | 0.9–1.3 | 0.295 |
| CA19-9 (kU/L) | |||||||
| ≥300 | 611 | ||||||
| <300 | 524 | 0.55 | 0.48–0.64 | 0.001 | 1.5 | 1.2–1.7 | <0.001 |
| Unknown CA19-9 | 159 | ||||||
| NLR | |||||||
| <4 | 581 | ||||||
| ≥4 | 713 | 1.5 | 1.2–1.6 | 0.001 | 1.3 | 1.1–1.7 | 0.0011 |
| LMR | |||||||
| <1.6 | 491 | ||||||
| ≥1.6 | 803 | 0.69 | 0.61–0.79 | 0.001 | 0.8 | 0.7–0.99 | 0.0383 |
| PLR | |||||||
| <180 | 590 | ||||||
| ≥180 | 704 | 1.2 | 1.1–1.4 | 0.004 | 1.0 | 0.9–1.2 | 0.625 |
| CAR | |||||||
| <0.4 | 561 | ||||||
| ≥0.4 | 636 | 1.8 | 1.61–2.1 | 0.001 | 1.4 | 1.2–1.7 | <0.001 |
| Unknown CRP | 97 | ||||||
| IBI | |||||||
| <30 | 689 | ||||||
| ≥30 | 552 | 0.57 | 0.51–0.65 | 0.001 | 0.65 | 0.6–0.8 | <0.001 |
| Unknown IBI | 53 | ||||||
NLR—neutrophil to lymphocyte ratio; PLR—platelet to lymphocyte ratio; LMR—lymphocyte to monocyte ratio; CAR—CRP to albumin ratio; IBI—inflammatory benchmark index; CRP—C-reactive protein.